Implications of the Omnibus Bill for Medical Device Security

This guide discusses the implications of the December 2022 Omnibus Bill on medical device manufacturers, particularly focusing on the new powers granted to the FDA regarding product security. It outlines three key takeaways: the FDA's approach to security, post-market considerations, and remediation and reporting processes. The FDA aims to enhance trustworthiness, transparency, and resilience in medical devices, emphasizing the importance of software bills of material (SBOMs) for managing software components. Manufacturers are encouraged to adopt a proactive approach to lifecycle product security, ensuring that SBOMs are generated and managed effectively. The guide also details the importance of timely cybersecurity risk management and the role of SBOMs in compliance with FDA regulations. It highlights that while current guidelines are not enforceable, they are expected to evolve into requirements, underscoring the need for manufacturers to adapt their practices accordingly.